Anavex Life Sciences Corp. (AVXL - Free Report) was a big mover last session, as its shares rose over 16% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company since Jun 2013, as the stock is now up 45.5%.
None of the estimates for this stock were revised over the past 30 days. The Zacks Consensus Estimate also remained unchanged over the same time frame. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Anavex Life Sciences currently has a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%
A better-ranked Medical-Biomed/Gene stock is Innoviva, Inc. (INVA - Free Report) which sports a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Anavex Life Sciences Corp. (AVXL - Free Report) was a big mover last session, as its shares rose over 16% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company since Jun 2013, as the stock is now up 45.5%.
None of the estimates for this stock were revised over the past 30 days. The Zacks Consensus Estimate also remained unchanged over the same time frame. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Anavex Life Sciences currently has a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%
A better-ranked Medical-Biomed/Gene stock is Innoviva, Inc. (INVA - Free Report) which sports a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on INVA - FREE
Get the latest research report on AVXL - FREE